Search alternatives:
significantly mediated » significantly predicted (Expand Search), significantly related (Expand Search), significantly reduced (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
mediated decrease » mediated defense (Expand Search), estimated decrease (Expand Search), mediated diseases (Expand Search)
decrease reversal » increases reversal (Expand Search)
significantly mediated » significantly predicted (Expand Search), significantly related (Expand Search), significantly reduced (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
mediated decrease » mediated defense (Expand Search), estimated decrease (Expand Search), mediated diseases (Expand Search)
decrease reversal » increases reversal (Expand Search)
-
61
-
62
-
63
-
64
-
65
Mylipb decreases tbk1-mediated irf3 phosphorylation and cellular antiviral response.
Published 2024“…(K) Overexpression of <i>mylipb</i> decreases tbk1-mediated decline of copy number of SVCV genes in SVCV-infected EPC cells. …”
-
66
-
67
-
68
Echocardiography, electrocardiogram and sanger sequencing results of the probands.
Published 2024Subjects: -
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
Decreased regulatory T cells and increased monocytes are observed in peripheral blood of obese mice.
Published 2022Subjects: -
78
DataSheet_2_Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.pdf
Published 2023“…</p>Methods<p>Since MerTK is the prototypic efferocytosis receptor, we assessed whether the MerTK inhibitor MRX2843, which is currently in clinical trials, would reverse immune evasion and enhance immune-mediated clearance of leukemia cells.…”
-
79
DataSheet_1_Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.pdf
Published 2023“…</p>Methods<p>Since MerTK is the prototypic efferocytosis receptor, we assessed whether the MerTK inhibitor MRX2843, which is currently in clinical trials, would reverse immune evasion and enhance immune-mediated clearance of leukemia cells.…”
-
80